Canbex.co.uk - Welcome to Canbex Therapeutics
Provided by Alexa ranking,
canbex.co.uk has ranked
N/A in
N/A and
3,462,976 on the world.
canbex.co.uk reaches roughly
896 users per day and delivers about
26,865 users each month. The domain canbex.co.uk uses a Commercial suffix and it's server(s) are located in
N/A with the IP number
5.77.63.117 and it is a
.co.uk domain.
Canbex Therapeutics is dedicated to discovering new medicines for rare neurological diseases. Inspired by the call of patients and their families, our mission is to build on cutting-edge research by scientific pioneers to find effective new treatments for devastating disorders of the brain and nervous system. Canbex has re-focused its programs and ...
List of domain same IP 5.77.63.117
Search Results related to canbex.co.uk on Search Engine
-
Welcome to Canbex Therapeutics
https://www.canbex.co.uk/
Canbex Therapeutics is dedicated to discovering new medicines for rare neurological diseases. Inspired by the call of patients and their families, our mission is to build on cutting-edge research by scientific pioneers to find effective new treatments for devastating disorders of the brain and nervous system. Canbex has re-focused its programs and ...
DA: 57 PA: 40 MOZ Rank: 20
-
Canbex Therapeutics - a client of LBIC London BioScience ...
https://www.lbic.com/canbex-therapeutics
Canbex Therapeutics. Canbex Therapeutics is dedicated to improving the quality of life for people with multiple sclerosis through the treatment of spasticity, one of the disorder's most debilitating symptoms. The goal of the Canbex programme is to set a new standard in the treatment of spasticity, through improved tolerability.
DA: 49 PA: 48 MOZ Rank: 89
-
Canbex Group - A leading provider of CBG and CBD products.
https://canbexgroup.com/
Welcome To Canbex Group. Canbex Group is the industrial division of the Bast Crops Institution, located in Hlukhiv, Ukraine. We are growing CBD and CBG with low THC levels at a very large scale. The first Ukrainian group with an unlimited cultivation, transportation, storage, processing, sales, import and export license.
DA: 40 PA: 87 MOZ Rank: 40
-
Canbex Therapeutics Ltd - Company Profile and News ...
https://www.bloomberg.com/profile/company/2610302Z:LN
Canbex Therapeutics Ltd. Canbex Therapeutics Ltd. Researches and develops compounds for treatment of neurodegenerative diseases. The Company conducts business in the United Kingdom.
DA: 99 PA: 100 MOZ Rank: 94
-
Canbex Therapeutics - Crunchbase Company Profile & Funding
https://www.crunchbase.com/organization/canbex-therapeutics
Canbex Therapeutics is dedicated to treating spasticity in multiple sclerosis (MS) and other disorders. Spasticity is a debilitating and painful symptom that consists of involuntary spasms and stiffness of limbs and torso. The goal of the Canbex lead programme is to improve the lives of people with this serious and incurable disorder, and set a new.
DA: 6 PA: 60 MOZ Rank: 91
-
Canbex Therapeutics Ltd – UCLB
https://www.uclb.com/about/our-spinouts/canbex-therapeutics-ltd/
Canbex is a spinout of University College London (UCL) that was established to develop its proprietary VSN compound series. In addition to its pioneering scientific founders and clinical advisors, Canbex has assembled a skilled and focused management team. Development activities are carried out through leading CROs and CMOs.
DA: 26 PA: 36 MOZ Rank: 36
-
Canbex Therapeutics Receives £1.75 million (USD 2.8 ...
https://www.nationalmssociety.org/About-the-Society/News/Canbex-Therapeutics-Receives-%C2%A31-75-million-(USD-2
Canbex is a virtual, low-burn company that was set up as a vehicle for the development of the VSN compounds. Building on the expertise of its founders Canbex has assembled a highly experienced team with expertise in pharmacology, medicinal chemistry, preclinical and clinical development, finance and business development.
DA: 88 PA: 82 MOZ Rank: 97
-
Canbex Announces Start of Phase I Trial of Oral VSN16R in ...
https://www.nationalmssociety.org/About-the-Society/News/Canbex-Announces-Start-of-Phase-I-Trial-of-Oral-VS
Canbex Therapeutics Ltd. announced that it is beginning a phase I study in 72 healthy subjects, the first stage of determining the safety and effectiveness of its oral compound, VSN16R, for treating spasticity in people with MS (Canbex press release, November 4, 2013).
DA: 51 PA: 56 MOZ Rank: 39
-
Canbex Therapeutics Ltd receives new investment from Fast ...
http://www.uclb.com/2010/05/26/canbex-therapeutics-ltd-receives-new-investment-from-fast-forward/
Canbex is a virtual, low-burn company that was set up as a vehicle for the development of VSN compounds. Building on the expertise of its founders, Canbex has assembled a highly experienced team of experts in pharmacology, medicinal chemistry, preclinical and clinical development, finance and business development.
DA: 50 PA: 74 MOZ Rank: 47
-
Filing Patent and Trademark applications, UK, Europe | EIP
https://www.eip.com/uk/services/prosecution/
Prosecution. We are a top-tier firm of patent, trademark and design attorneys, providing a robust and broad intellectual property registration service in Europe and the US.
DA: 3 PA: 12 MOZ Rank: 16
Alexa Rank
GLOBAL RANK
Alexa Reach
Page length
Alexa Rank Country N/A
Daily Unique Visitors
Monthly Unique Visitors
Vistor via Country
Country lang
Country code
Total visitor
Country
Country code
Total visitor
Alexa Traffic Graph
Alexa daily traffic trend graph
Alexa daily pageviews (percent) graph
Alexa daily pageviews per user graph
Alexa time on site (in minutes) graph
Alexa bounce rate (percent) graph
Alexa search visits graph
SEOquake Zone
| Title |
|
Welcome to Canbex Therapeutics |
Tips |
| Description |
|
Canbex Therapeutics is dedicated to treating spasticity in multiple sclerosis (MS) and other disorders. The goal of the Canbex lead programme is to set a new standard in the treatment of spasticity, through improved tolerability. |
Tips |
| Keywords |
|
Canbex Therapeutics, treating spasticity, Multiple Sclerosis Society, VSN16R, Phase I human safety trials. |
Tips |
| Viewport |
|
width=device-width, initial-scale=1.0 |
Tips |
| Icon |
|
|
|
| UTF-8 |
|
|
|
Mini site formation by Alexa Rank
DNS Record
| Host |
Type |
Class |
TTL |
Extra |
| canbex.co.uk |
A |
IN |
3599 |
Ip: 5.77.63.117
|
| canbex.co.uk |
NS |
IN |
21599 |
Target: ns1.bdm.microsoftonline.com
|
| canbex.co.uk |
NS |
IN |
21599 |
Target: ns2.bdm.microsoftonline.com
|
| canbex.co.uk |
NS |
IN |
21599 |
Target: ns3.bdm.microsoftonline.com
|
| canbex.co.uk |
NS |
IN |
21599 |
Target: ns4.bdm.microsoftonline.com
|
| canbex.co.uk |
SOA |
IN |
3599 |
Mname: ns1.bdm.microsoftonline.com
Rname: azuredns-hostmaster.microsoft.com
Serial: 1
Refresh: 3600
Retry: 300
Expire: 2419200
Minimum-ttl: 300
|
| canbex.co.uk |
MX |
IN |
3599 |
Pri: 0
Target: canbex-co-uk.mail.protection.outlook.com
|
| canbex.co.uk |
TXT |
IN |
3599 |
Txt: mscid=q9Rs+5Y8R81z5FLjytrAY5pTGRGqASKAo0ZoSckrW8nLDI33F5hI5zPVVH1mb61uqw/I3b/kd9ZfVFDThjds9g==
Entries_0: mscid=q9Rs+5Y8R81z5FLjytrAY5pTGRGqASKAo0ZoSckrW8nLDI33F5hI5zPVVH1mb61uqw/I3b/kd9ZfVFDThjds9g==
|
| canbex.co.uk |
TXT |
IN |
3599 |
Txt: v=spf1 include:spf.protection.outlook.com -all
Entries_0: v=spf1 include:spf.protection.outlook.com -all
|
Hosting and Whois Zone
| IP |
5.77.63.117 |
| Domain infomation |
Error for "canbex.co.uk".
the WHOIS query quota for 128.199.13.166 has been exceeded
and will be replenished in 10 seconds
WHOIS lookup made at 03:22:12 27-Jan-2021
--
This WHOIS information is provided for free by Nominet UK the central registry
for .uk domain names. This information and the .uk WHOIS are:
Copyright Nominet UK 1996 - 2021.
You may not access the .uk WHOIS or use any data from it except as permitted
by the terms of use available in full at https://www.nominet.uk/whoisterms,
which includes restrictions on: (A) use of the data for advertising, or its
repackaging, recompilation, redistribution or reuse (B) obscuring, removing
or hiding any or all of this notice and (C) exceeding query rate or volume
limits. The data is provided on an 'as-is' basis and may lag behind the
register. Access may be withdrawn or restricted at any time.
|
